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ABSTRACT 
 
Objective: The objective of this selective EBM review is to determine whether or not MDMA-
assisted psychotherapy is an effective treatment for posttraumatic stress disorder (PTSD). 
 
Study Design: Systematic review of three published, randomized controlled trials (double-blind, 
placebo-controlled) between 2008-2013. 
 
Data Sources: All articles used were published in English, in peer-reviewed journals, and found 
using PubMed/MEDLINE and Cochrane Review databases. 
 
Outcomes Measured: The primary outcome measure in all three studies was the severity of 
PTSD symptoms. The primary outcome measure was assessed using the Clinician-Administered 
PTSD Scale (CAPS) and the Severity of Symptoms Scale for PTSD (SSSPTSD). 
 
Results: All trials demonstrated a larger group mean reduction in CAPS/SSSPTSD scores for the 
MDMA group compared to the placebo group. One study found these results to be statistically 
significant (P = 0.015) and a considerable clinical response was seen with the MDMA-AP group 
with a NNT of 2. 
 
Conclusions: Based on the studies, all reported that the use of MDMA-AP reduced group mean 
scores from baseline to a larger extent than placebo. Although the studies showed a similar 
outcome, further studies with larger, heterogeneous sample sizes need to be performed to assess 
the safety and efficacy of MDMA-AP as a treatment for PTSD. 
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INTRODUCTION 
Posttraumatic stress disorder (PTSD) is a highly prevalent and costly mental health 
disorder that often causes significant impairment in multiple areas of functioning.1 The lifetime 
prevalence of PTSD in the United States is approximately 8%, with rates differing between 
females and males at 10% and 4%, respectively.2 Comorbidities are common among PTSD 
sufferers, with 66% of those diagnosed having two or more psychiatric and/or medical issues, 
such as depressive disorders, anxiety disorders, and/or substance-related disorders.3 The exact 
cost and number of healthcare visits due to PTSD have yet to be determined, though a study 
performed by the Congressional Budget Office found the average costs for the first year of 
treatment among veterans to be approximately $8,300 per patient.4 In addition, approximately 
45-60% of mental health issues are treated in primary care, with primary care typically being the 
location of the first presentation for those with disturbances due to psychiatric reasons.2 
PTSD is a psychiatric illness that commonly manifests in individuals who have witnessed 
or experienced a traumatic life event, such as death, disastrous injury, or sexual abuse. The 
development of PTSD does not occur in all individuals who have experienced a traumatic event, 
though some have certain risk factors and preexisting conditions that make them more 
susceptible than others. These risk factors, such as being female and the presence of childhood 
trauma, combined with biological theories suggesting hypothalamo-pituitary-adrenal axis 
overactivity, autonomic nervous system overactivity, and alterations in norepinephrine levels and 
receptors, contribute to the evolution of PTSD.1  Common symptoms that are characteristic of 
PTSD include flashbacks, nightmares, distressing dreams or memories, sleep disturbances, 
hypervigilance, exaggerated startle response, and avoidance of thoughts, objects, people, or 
places that remind the patient of the traumatic event. According to the Diagnostic and Statistical 
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Manual of Mental Disorders (DSM-5), a diagnosis of PTSD can be given to patients over 6 years 
of age who meet the following criteria: (a) exposure to actual or threatened death, serious injury, 
or sexual violence; (b) presence of at least one intrusion symptom; (c) persistent avoidance 
symptoms; (d) negative alterations in cognitions and mood associated with the traumatic event; 
(e) marked alterations in arousal and reactivity associated with the traumatic event; (f) duration 
of the disturbance is more than one month; (g) the disturbance causes clinically significant 
distress or impairment in social, occupational, or other important areas of functioning; and (h) 
the disturbance is not attributable to the physiological effects of a substance or another medical 
condition.1 
Current treatment options for PTSD include pharmacotherapy and psychotherapy. Two 
pharmacotherapeutic agents – sertraline (Zoloft) and paroxetine (Paxil) – have FDA approval for 
the treatment of PTSD.5,6 Cognitive behavioral therapy (CBT) and prolonged exposure therapy 
(PE) are well known psychotherapeutic options that, although effective, have substantial dropout 
rates.7,8 Patients undergoing CBT or PE are asked to recollect their frightening memories many 
times within a secure setting with the goal of inducing elimination of the undesirable trauma/fear 
response. The psychotherapeutic treatment, however, is an arduous process that is 
psychologically and emotionally taxing and commonly exacerbates symptoms before they 
meliorate.8 Patients often feel overwhelmed during therapy and avoidance behavior – a hallmark 
symptom of PTSD – often overpowers their ability to persevere through psychotherapy 
sessions.9 Additionally, many PTSD patients have difficulty building interpersonal and trusting 
bonds – an essential component to successful treatment. Seeing that 70-80% of those with PTSD 
are unresponsive to pharmacotherapeutics and dropout rates in psychotherapeutic trials range 
from 20-30%, it is evident that novel therapeutic options must emerge.7,8,9 
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MDMA (Methylenedioxymethamphetamine)-assisted psychotherapy (MDMA-AP) is a 
developing method that has shown promise in clinical trials for the treatment of PTSD. MDMA-
AP utilizes a psychoactive drug called MDMA as an adjunct to psychotherapy. The subjective 
psychological effects of MDMA include diminished anxiety, reduced depression, increased 
relaxation, euphoria, elevated feelings of trust, expanded insight, and mitigated fear response.1 It 
is hypothesized that MDMA, when given in a safe context, produces unique psychological 
effects that allow those with PTSD to engage in, optimize, and endure psychotherapy sessions. 
OBJECTIVE 
 The objective of this selective EBM review is to determine whether or not MDMA-AP is 
an effective treatment for PTSD. 
METHODS 
 The criteria used in the selection of the three randomized controlled trials (RCTs) for this 
review were patients 18 years or older who met DSM-III-R, DSM-IV, or DSM-IV-R 
requirements for PTSD. The intervention that was studied was MDMA-AP. MDMA-AP needed 
to be compared to psychotherapy with concomitant administration of either active placebo or 
inactive placebo. Two articles compared psychotherapy with concomitant MDMA administration 
to the same psychotherapy accompanied by inactive placebo administration. One article 
compared psychotherapy with concomitant full-dose (125 mg) MDMA administration to the 
same psychotherapy accompanied by low-dose (25 mg) MDMA administration. The outcomes 
measured were a reduction in the severity of symptoms associated with PTSD. Studies utilized in 
this selective EBM review included three randomized, double, placebo controlled clinical trials.  
Two databases were used (PubMed/MEDLINE and Cochrane Library) to find all three 
articles on MDMA-AP. The search included the terms “MDMA” and “PTSD.” All articles were 
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written in English and published in peer-reviewed journals between the years 2008 and 2013. 
The articles were selected based on their relevance to the clinical question and for their focus on 
patient-oriented outcomes (POEMs). Inclusion criteria comprised studies that were RCTs with 
publication dates from 2004 to present. Exclusion criteria consisted of patients under the age of 
18, as well as pregnant and/or lactating women. The statistics included were mean change from 
baseline, p-values, and numbers needed to treat (NNT). Table 1 demonstrates the demographics 
and characteristics of the studies chosen for this review. 
Table 1. Demographics and characteristics of included studies 
Study Type #pts Age 
(yrs) 
Inclusion Criteria Exclusion Criteria W/D Interventions 
Bouso et al 
(2008)7 
Randomized, 
double blind, 
placebo 
control 
6 29 - 
49 
-Women with 
chronic, treatment-
resistant PTSD 
secondary to sexual 
assault 
- Score > 15 on 
SSSPTSD 
-Pregnant women 
-Medication usage 
in the month prior 
to the start of the 
study 
0 -MDMA 50-75 
mg (n=4); 
placebo (n=2) 
-MDMA or 
placebo given 
during one 6-
hour 
experimental 
psychotherapy 
session 
Mithoefer 
et al 
(2011)8 
Randomized, 
double blind, 
placebo 
control 
23 21 - 
70 
Men and women 
aged 21-70 years 
who meet DSM-IV-
R criteria for the 
diagnosis of crime 
or war-related 
chronic PTSD and 
have treatment-
resistant symptoms, 
defined as a CAPS 
score of greater than 
or equal to 50 
following at least 3 
months of prior 
SSRI or SNRI 
treatment in addition 
to at least 6 months 
of psychotherapy. 
-Freedom from any 
major medical 
conditions 
-Borderline 
Personality 
Disorder or any 
current Axis I 
Disorder 
(exceptions: anxiety 
disorders, affective 
disorders other than 
bipolar disorder 
type 1, substance 
abuse or 
dependence in 
remission for 
greater than or 
equal to 60 days, 
and eating disorder 
without active 
purging) 
2 -MDMA 125 
mg (n=12); 
placebo (n=8) 
-MDMA or 
placebo given 
during two 8-
hour 
experimental 
psychotherapy 
sessions 
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Oehen et 
al (2013)9 
Randomized, 
double blind, 
active control 
14 23 - 
67 
Men and women 
who met the DSM-
IV-text revision 
(TR) criteria for 
PTSD with 
treatment-resistant 
symptoms, as 
indicated by a 
CAPS score of 
greater than or equal 
to 50 and having 
previously 
undergone at least 6 
months of 
psychotherapy and 3 
months of treatment 
with an SSRI. 
-Significant medical 
conditions, except 
for hypothyroidism 
under hormonal 
replacement 
-Psychiatric 
conditions: hx of 
psychotic illness, 
bipolar disorder 
type I, borderline 
personality 
disorder, 
dissociative identity 
disorder, and 
substance abuse or 
dependence within 
60 days of 
enrollment 
-Use of MDMA on 
more than five 
occasions or less 
than 6 months prior 
to enrollment 
2 -MDMA 25 mg 
+ 12.5 mg 2.5 
hours later 
(n=4); MDMA 
125 mg + 62.6 
mg 2.5 hours 
later (n=8) 
-MDMA or 
placebo given 
during three 8-
hour 
experimental 
psychotherapy 
sessions 
 
 
OUTCOMES MEASURED 
 The severity of PTSD symptoms was the primary outcome measure in the selected 
studies. In the Bouso et al study, outcome measures used were the Severity of Symptoms Scale 
for Posttraumatic Stress Disorder (SSSPTSD) which assesses the main symptoms of PTSD.7 In 
the Mithoefer et al study, outcome measures used include the Clinician-Administered PTSD 
Scale (CAPS). The CAPS quantifies PTSD symptoms.8 In the Oehen et al study, outcome 
measures used were a widely-used German version of the CAPS. 
RESULTS 
 The Bouso et al study7 performed in 2008 was a double blind RCT consisting of 6 
patients with treatment-resistant PTSD (failed at least 1 prior treatment for PTSD) and a baseline 
SSSPTSD larger than 15. Of these patients, 3 received 50 mg MDMA, 1 received 75 mg 
MDMA, and 2 received placebo. Each patient endured 7 psychotherapy sessions of 1 hour 30 
minutes’ duration, with only 1 psychotherapy period coexisting with MDMA or placebo. This 
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experimental psychotherapy session was the 4th session out of a total of 8 sessions and 
commenced with either MDMA or placebo ingestion. The experimental session lasted a total of 
6 hours. Baseline and post-treatment SSSPTSD scores were calculated and results were reported 
as a group mean change from baseline. The results from this study showed larger improvements 
in group mean score for the MDMA group compared to the placebo group, with a mean 
SSSPTSD score reduction of 9 for the MDMA group vs 4.5 for the placebo group. These 
changes correspond to a 24.1% average reduction for the MDMA group compared to 10.1% 
reduction for the placebo group (Table 2). The difference between the mean change from 
baseline was primarily powered by greater decreases in the reexperiencing and avoidance 
subdivisions of the SSSPTSD.7 It should be noted that the patient receiving 75 mg of MDMA 
plus psychotherapy achieved a 16 point SSSPTSD score reduction. The results of the 75 mg 
MDMA group were not considered here because there was only 1 patient in this group. Due to 
the small size of the study, a statistical analysis between groups was not performed.7 
Table 2. Mean SSSPTSD scores by group over time (pre-to post treatment) 
 
 The Mithoefer et al study8 conducted in 2011 was a double blind RCT consisting of 20 
patients with treatment-resistant PTSD (as outlined in Table 1). The study initially enrolled 23 
patients, but 1 dropped out due to a relapse of depression, another due to issues with travel 
expenses, and a 3rd was removed after an assessment revealed he was not treatment-resistant. The 
2 experimental psychotherapy sessions (sessions 1 and 5; 8 hours per session) in this study were 
performed with patients either receiving 125 mg MDMA or inactive placebo. Additionally, all 
patients underwent 11 nondrug psychotherapy sessions, with each session lasting for 90 minutes. 
CAPS scores were recorded at baseline (T1), 4 days after each of the 2 experimental sessions 
Group Baseline Post-treatment Mean Reduction 
from Baseline 
Average Reduction 
(%) 
MDMA 50 mg (n=3) 37.3 28.3 9 24.1 
Placebo (n=2) 44.5 40 4.5 10.1 
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(T2, T3), and 60 days after the final experimental session (T4). The results of this study showed 
mean CAPS scored improved over time in both groups (group vs time interaction p < 0.0005). 
The MDMA group, however, showed significantly greater improvement compared to the 
placebo group (group vs time interaction, p = 0.015) with a 68% reduction vs 25.2% reduction at 
2 months following the second experimental session, respectively (Table 3). A clinically 
significant response was defined as a > 30% reduction from baseline in CAPS total severity 
score.8 The results showed that 83.3% (10/12 patients) of the MDMA-AP group and 25% (2/8) 
of the placebo plus psychotherapy group achieved a clinical response. Furthermore, 10 patients 
of the MDMA group no longer fulfilled DSM-IV requirements for PTSD compared with 2 
patients of the placebo group.8 The absolute benefit increase (ABI) was calculated to be 58.3% 
and the relative benefit increase (RBI) was calculated to be 233%, with a corresponding NNT of 
2 (Table 4). 
Table 3. Mean CAPS scores by group over time 1 (T1) – time 4 (T4) 
Group Baseline 
(T1) 
T2 T3 T4 Mean 
Reduction 
from 
Baseline 
Average 
Reduction 
(%) 
P-value 
MDMA (n=12) 79.2 37.8 29.3 25.5 53.7 68 0.015 
Placebo (n=8) 79.6 74.1 66.8 59.1 20.5 25.2  
 
Table 4. Clinical response and treatment effects of MDMA-AP 
Study EER CER ABI RBI NNT 
Mithoefer et al, 
2011 
83.3% 25% 58.3% 233% 2 
 
 The Oehen et al study9 conducted in 2013 was a double blind RCT consisting of 12 
patients with treatment-resistant PTSD (as outlined in Table 1). The study initially enrolled 14 
patients, but 2 patients withdrew because of adverse events after the first experimental session. 
The three experimental psychotherapy sessions were 8 hours in duration and were performed 
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with patients either receiving high-dose MDMA (125 mg + 62.5-mg supplementary dose) or 
low-dose MDMA (25 mg + 12.5-mg supplementary dose; “active placebo”). The experimental 
sessions were intermixed with 12 weekly nondrug psychotherapy sessions of shorter duration. 
CAPS scores were calculated at baseline (T0) and 3 weeks after the second (T1) and third (T2) 
experimental sessions. CAPS scores were analyzed using 2-way ANOVA.9 The results indicated 
CAPS mean scores increased from T0-T2 for the active placebo group and decreased from T0-
T2 for the high-dose MDMA group. Although there was a trend toward larger effects from 
higher-dose MDMA, these results were not statistically significant (p = 0.066, Table 5). 
Table 5. Effects of high-dose MDMA-AP vs low-dose MDMA-AP on mean CAPS scores 
Group T0 T1 T2 Mean Change 
from Baseline 
Average 
Change (%) 
P-value 
High-dose 
MDMA (n=8) 
66.4 63.0 50.8 - 15.6 - 23.5 0.066 
Low-dose 
MDMA (n=4) 
63.4 60.0 66.5 + 3.1 + 4.9  
 
After the clinical trial, an open-label phase was initiated which allowed the 4 patients who had 
received low-dose MDMA to receive 6 sessions of high-dose MDMA-AP. At one year following 
completion of the open-label phase, average CAPS scores decreased by 52% (35 points) in these 
4 patients. At one year follow-up, 5 of 12 subjects no longer fulfilled diagnostic requirements for 
PTSD, 4 had moderate PTSD, 2 subjects reduced their PTSD severity level to mild. Furthermore, 
one patient on disability and three patients on limited employment were able to go back to work 
as full-time employees by the one year follow-up.9 
 There were no significant drug-related adverse events in any of the studies. Mithoefer et 
al. did note larger increases in blood pressure, heart rate, and body temperature in the MDMA 
group, but these effects resolved and returned to baseline in both groups at the end of each 
experimental session.8 
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DISCUSSION 
 This systemic review evaluated the three randomized controlled trials evaluated the 
effectiveness of MDMA-AP as a treatment for PTSD. The study by Bouso et al. demonstrated 
encouraging indications of efficacy through reductions in SSSPTSD scores for both groups, 
although there were larger reductions in the MDMA-AP group (24.1%) vs placebo group 
(10.1%) that were principally fueled by larger decreases in reexperiencing and avoidance. This 
study, however, has an array of limitations due to its small sample size and enrollment of only 
female subjects. Additionally, the ethnicity of the subjects was not reported and a statistical 
analysis was not completed. The Mithoefer et al. study generated clinically and statistically 
significant improvements in PTSD symptomatology as calculated by CAPS scores and a p-value 
equal to 0.015 and a NNT of 2. Furthermore, 83.3% of the MDMA-AP group subjects no longer 
met diagnostic criteria for PTSD. The drawbacks to this study include a small sample size 
composed solely of Caucasians, with nearly 85% of these being female. The Oehen et al. study 
showed a reduction in CAPS scores over time, with a trend toward larger effects from higher-
dose MDMA, although these results were not statistically significant (p = 0.066). Weaknesses in 
this study include a small sample size composed entirely of Europeans, with most participants 
being female. An additional pitfall is that all three RCTs in this systemic review exclusively 
enrolled and treated subjects with chronic, treatment-resistant PTSD. 
 From a clinical standpoint, safety, affordability, and access are strong considerations 
when making treatment decisions. Unfortunately, MDMA-AP may miss the mark in all three 
categories. Although the trials demonstrated no serious drug-related adverse events, MDMA 
intoxication has been known to cause hyperthermia, hyponatremia, seizures, hepatotoxicity, and 
life-threatening increases in heart rate and blood pressure.6 These serious events, although 
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uncommon, limit the patient population that could benefit from this type of therapy. 
Affordability of MDMA may be another forceful disadvantage considering the 6-8-hour length 
of the therapy sessions and extended monitoring of patients, which often includes overnight 
observation.7,8,9 Finally, with no current FDA-approved indications and a schedule I drug status, 
medical access to MDMA is nearly impossible.6,7 
CONCLUSION 
 The studies reviewed demonstrate inconclusive evidence as to whether or not MDMA-
assisted psychotherapy (MDMA-AP) is an effective treatment for posttraumatic stress disorder 
(PTSD). Although all studies demonstrated obvious improvements in CAPS scores for MDMA 
versus placebo, only one study showed statistical significance. Future studies will need larger 
sample sizes and a heterogeneous group of patients to apply clinically and statistically significant 
findings to a more global population. Additionally, future studies need to focus on comparing the 
effectiveness MDMA-AP to other treatment options, such as the combined gold-standard 
psychotherapy with SSRI therapy. For many, the use of MDMA-AP greatly reduced debilitating 
PTSD symptoms, removed a PTSD diagnosis, and/or allowed a return to employment as a full-
time employee. These quality of life improvements are patient-oriented outcomes that cannot be 
overlooked or forgotten. PTSD is a costly condition with the potential for devastating outcomes, 
and further MDMA-AP studies need to be performed to assess its safety and clarify its 
effectiveness as a treatment option for this common psychiatric illness. 
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